Clinical trials: Stereotactic Body Radiation Therapy
Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment…
- Trial name
- NCT04729959
- Testing
- Atezolizumab, Biospecimen Collection, Conventional Surgery
- Where
- 110 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
The purpose of this study is to find out the effectiveness stereotactic body radiation therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as treatment for operable stage II to III non-small…
- Trial name
- SACTION01 (NCT05319574)
- Testing
- SBRT, Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Metastatic Breast Cancer, Metastatic Colorectal Cancer
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers
The proposed theory is based on combination of radiation therapy with usual targeted therapies capable of ADCC (Antibody-Dependant Cell Cytotoxicity).
- Conditions
- Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Head and Neck Cancer
- Trial name
- IRAM (NCT03323424)
- Testing
- Systemic treatment + Stereotactic Body Radio-Therapy (SBRT), Systemic treatment
- Where
- 6 sites in France
- Sponsor
- Institut de Cancérologie de la Loire
Prostate Cancer, Radiotherapy
Observational Study on Extreme Hypofractionation for Localized Prostate Cancer
Radiotherapy (RT) is an established treatment option for localized prostate cancer (PCa), with cure rates similar to those of radical prostatectomy.
- Conditions
- Prostate Cancer, Radiotherapy, SBRT
- Trial name
- OBELIX PCa (NCT05344235)
- Testing
- SBRT
- Where
- Belgium
- Volunteers
- 246 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer Early Stage Breast Cancer (Stage 1-3), SBRT
A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial
Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery.
- Trial name
- DESERT-I (NCT06671691)
- Testing
- SBRT level I, SBRT level II, SBRT level III
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Universitat de les Illes Balears
Solid Tumor, Oligometastases
SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases
The SOFT study will evaluate the feasibility and safety of MR-guided stereotactic ablative radiotherapy (SABR) for infra-diaphragmatic soft tissue metastases.
- Conditions
- Solid Tumor, Oligometastases, Soft Tissue Disease
- Trial name
- SOFT (NCT04407897)
- Testing
- Stereotactic radiotherapy
- Where
- Denmark
- Volunteers
- 121 people
- Sponsor
- Herlev Hospital
Pancreatic Cancer, Pancreas Cancer
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
- Trial name
- NCT02950025
- Testing
- Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Non-Small Cell Lung Cancer
Improving Pulmonary Function Following Radiation Therapy
The purpose of this study is to develop radiation plans that will help preserve lung function in healthy tissue surrounding the tumor.
- Trial name
- NCT02843568
- Testing
- Laboratory Biomarker Analysis, Standard fractionation, Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- University of Wisconsin, Madison
Stereotactic Body Radiation Therapy, Lung Lesions
Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Cancer
This is a single-center prospective cohort study evaluating the impact of a simple audio recording hypnosis system on the occurrence of artifacts on 4D CT scans in patients requiring SBRT radiotherapy for lung lesions (peripheral…
- Trial name
- HYPNOCT-4D (NCT07334990)
- Testing
- Hypnotic record
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Hepatocellular Carcinoma
Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy
Radiation therapy is a highly effective modality for managing localized solid tumors and has become a fundamental component of treating unresectable hepatocellular carcinoma.
- Trial name
- NCT06379256
- Testing
- Photon or proton radiotherapy
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Chang Gung Memorial Hospital
Pancreatic Cancer
SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent Pancreatic Cancer Patients
When gemcitabine based chemo and fluorouracil based chemo regimes are failed in late-stage or recurrent pancreatic cancer patients, there is no alternative options. Anti-PD-1 antibody has became a promising anti-cancer drug.
- Trial name
- CISPD-2 (NCT03716596)
- Testing
- SBRT, anti-PD-1 antibody
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Melanoma
Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)
This study is a phase I/II, multicenter, open-label study starting with a phase I part followed by a Phase II part. The phase I part of the study aims at evaluating the safety and efficacy (in terms of abscopal effect at week 6)…
- Trial name
- NCT03354962
- Testing
- Nivolumab + Ipilimumab, Combined treatment schema
- Where
- 6 sites in France
- Volunteers
- 6 people
- Sponsor
- Institut Claudius Regaud
Brain Metastases, Adult
SIMT Stereotactic Radiosurgery Outcomes Study
The purpose of this study is to determine the effectiveness and efficiency of Single Isocenter Multi-target Stereotactic Radiosurgery (SIMT SRS) in patients with four or more brain metastases
- Trial name
- SIMT (NCT02886572)
- Testing
- Stereotactic radiosurgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Prostate Adenocarcinoma, Stage I Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer
This clinical trial studies stereotactic body radiation therapy in treating patients with low- and intermediate-risk prostate cancer.
- Trial name
- NCT01737151
- Testing
- stereotactic body radiation therapy, four fraction split-course SBRT
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Prostate Boost Irradiation With Stereotactic Body RT (SBRT)
A randomized controlled open-label trial in patients with high risk prostate cancer. Eligible and consenting patients will be randomly allocated to receive stereotactic body radiotherapy (SBRT) boost to prostate or conventional…
- Trial name
- PBS (NCT03380806)
- Testing
- LHRH agonist, Pelvic Radiation, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Juravinski Cancer Center
Prostate Cancer
Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate Cancer
The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (35 Gy / 5 fractions / 29 days) for the treatment of low-risk prostate cancer.
- Trial name
- pHART3 (NCT01578902)
- Testing
- Stereotactic ablative body radiotherapy
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- Sunnybrook Health Sciences Centre
Liver Cancer
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
This trial will provide the maximum tolerated dose for radiation therapy for liver tumors and describe the toxicity profile using the vGRID therapy technique.
- Trial name
- vGRID SBRT (NCT05727787)
- Testing
- Stereotactic Body Radiation Treatment
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Kansas Medical Center
Lung Cancer
Respiratory Adaptive Computed Tomography: Feasibility Study on Real-Time Gated 4DCT for Lung Cancer Radiotherapy
This study does not involve a therapeutic intervention as standard radiation therapy treatment will be prescribed. This study involves one additional 4DCT scan (i.e.
- Trial name
- REACT (NCT05030207)
- Testing
- Real-time Gated 4DCT, Conventional 4DCT
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- University of Sydney
NSCLC
A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation
This study is a single-arm phase II, multicenter study designed to evaluate the activity of stereotactic radiotherapy plus the continuation of durvalumab for 12 more months for patients presenting with NSCLC metachronous…
- Trial name
- SILK BM (NCT03955198)
- Testing
- Radiotherapy + durvalumab
- Where
- 8 sites in France
- Volunteers
- 4 people
- Sponsor
- Institut Claudius Regaud
Bladder Urothelial Carcinoma
A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer
The researchers are doing this study to find out whether stereotactic body radiation therapy (SBRT) in combination with immunotherapy (cemiplimab with or without fianlimab) before cystectomy is an effective and safe treatment for…
- Trial name
- NCT07414992
- Testing
- Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab
- Where
- 7 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.